DKFZ 30 records found  1 - 10nextend  jump to record: Search took 0.00 seconds. 
DBCoverage [DKFZ-2022-02487] Journal Article
; ; ; et al
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
Licensed L1-VLP-based immunizations against high-risk mucosal human papillomavirus (HPV) types have been a great success in reducing anogenital cancers, although they are limited in their cross-protection against HPV types not covered by the vaccine. Further, their utility in protection against cutaneous HPV types, of which some contribute to non-melanoma skin cancer (NMSC) development, is rather low. [...]
[DKFZ-2022-02473] Journal Article
; ; ; et al
Framework and baseline examination of the German National Cohort (NAKO).
The German National Cohort (NAKO) is a multidisciplinary, population-based prospective cohort study that aims to investigate the causes of widespread diseases, identify risk factors and improve early detection and prevention of disease. Specifically, NAKO is designed to identify novel and better characterize established risk and protection factors for the development of cardiovascular diseases, cancer, diabetes, neurodegenerative and psychiatric diseases, musculoskeletal diseases, respiratory and infectious diseases in a random sample of the general population. [...]
[DKFZ-2022-02373] Journal Article
; ; ; et al
TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing.
IDH mutant gliomas are grouped into astrocytomas or oligodendrogliomas depending on the co-deletion of chromosome arms 1p and 19q. Although the genomic alterations of IDH mutant gliomas have been well described, transcriptional changes unique to either tumor type have not been fully understood. [...]
pmc [DKFZ-2022-01607] Journal Article
; ; ; et al
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Annals of oncology 28(10), 2472 - 2480 () [10.1093/annonc/mdx355]  GO
Intratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is uncertain. A prospective, single-arm, translational study using targeted multiregion prostate biopsies was carried out to study genomic and T-cell ITH in clinically high-risk PC aiming to identify drivers and potential therapeutic strategies.Forty-nine men with elevated prostate-specific antigen and multiparametric-magnetic resonance imaging detected PC underwent image-guided multiregion transperineal biopsy. [...]
[DKFZ-2022-01147] Journal Article
; ; ; et al
Data protection-compliant broad consent for secondary use of health care data and human biosamples for (bio)medical research: towards a new German national standard.
The secondary use of deidentified but not anonymized patient data is a promising approach for enabling precision medicine and learning health care systems. In most national jurisdictions (e.g., in Europe), this type of secondary use requires patient consent. [...]
DBCoverage [DKFZ-2022-00622] Journal Article
; ; ; et al
Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation.
Notably, the majority of papillomaviruses associated with a high cancer risk have the potential to translate different isoforms of the L1 major capsid protein. In an infection model, the cutaneous Mastomys natalensis papillomavirus (MnPV) circumvents the humoral immune response of its natural host by first expressing a 30 amino acid extended L1 isoform (L1LONG). [...]
DBCoverage [DKFZ-2022-00529] Journal Article
; ; ; et al
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8.
Science advances 8(12), eabh4050 () [10.1126/sciadv.abh4050]  GO
Radiotherapy is a mainstay cancer therapy whose antitumor effects partially depend on T cell responses. However, the role of Natural Killer (NK) cells in radiotherapy remains unclear. [...]
[DKFZ-2022-00171] Journal Article
; ; ; et al
Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
To provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management.We used data from 3,184 BRCA1 and 2,157 BRCA2 families in the Consortium of Investigators of Modifiers of BRCA1/2 to estimate age-specific relative (RR) and absolute risks for 22 first primary cancer types adjusting for family ascertainment.BRCA1 PVs were associated with risks of male breast (RR = 4.30; 95% CI, 1.09 to 16.96), pancreatic (RR = 2.36; 95% CI, 1.51 to 3.68), and stomach (RR = 2.17; 95% CI, 1.25 to 3.77) cancers. Associations with colorectal and gallbladder cancers were also suggested. [...]

DKFZ : 30 records found   1 - 10nextend  jump to record:
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.